# US 2026/0284125 A1 · Microbial consortium and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0284125 A1
- Document ID: US20260284125A1
- Status: Published application
- Kind: A1
- Application number: 19/460,159
- Filed: 2026-01-26
- Published: 2026-09-24
- Earliest claimed: 2016-03-04
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Susan LYNCH; Nikole KIMES; Din LIN; Ricardo VALLADARES; Kei FUJIMURA
- Web page: https://patentgrep.com/patent/US20260284125A1

## CPC

- A61K 35/745: Bifidobacteria
- A23L 29/065: {Microorganisms (addition of bacteria for nutritional purposes A23L33/135)}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/02: Bacterial antigens
- A61K 39/35: Allergens
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are, inter alia, microbial compositions and methods of using the same. The microbial compositions provided include, inter alia, therapeutically effective amounts of Lactobacillus johnsonii, Faecalibacterium prausnitzii, Akkermansia muciniphila, Myxococcus xanthus and Pediococcus pentosaceus and are particularly useful for methods of treating and for methods of preventing inflammatory diseases.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A pharmaceutical composition comprising a purified bacterial population comprising Pediococcus sp., Myxococcus sp., and Clostridium sp., wherein the Pediococcus sp. comprises Pediococcus pentosaceus, wherein the Myxococcus sp. comprises Myxococcus xanthus, and wherein the Clostridium sp. comprises Clostridium hiranonis.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the pharmaceutical composition further comprises an auxiliary agent comprising lubricants, preservatives, stabilizers, buffers, coloring, or a combination thereof.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the pharmaceutical composition further comprises an excipient comprising water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, or a combination thereof.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is a capsule, a tablet, or a suspension.

### Claim 33

A pharmaceutical composition comprising a purified bacterial population comprising Pediococcus sp., Cystobacter sp., and Clostridium sp., wherein the Pediococcus sp. comprises Pediococcus pentosaceus, wherein the Cystobacter sp. comprises Cystobacter fuscus, and wherein the Clostridium sp. comprises Clostridium hiranonis.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the pharmaceutical composition further comprises an auxiliary agent comprising aromatic substances, wetting agents, emulsifiers, salts, or a combination thereof.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the pharmaceutical composition further comprises an excipient comprising alcohols, oils, gelatins, carbohydrates, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, or a combination thereof.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, wherein the pharmaceutical composition is a suppository, a powder, or a cream.

### Claim 37

A method for treating or preventing an allergic inflammation in a subject in need thereof, comprising administering to the subject with a pharmaceutical composition comprising a purified bacterial population, wherein the purified bacterial population comprises Myxococcus sp., Cystobacter sp., and Clostridium sp.

### Claim 38 (depends on 37)

The method of claim 37, wherein the Myxococcus sp. comprises Myxococcus xanthus.

### Claim 39 (depends on 38)

The method of claim 38, wherein the Cystobacter sp. comprises Cystobacter fuscus.

### Claim 40 (depends on 39)

The method of claim 39, wherein the Clostridium sp. comprises Clostridium hiranonis.

### Claim 41 (depends on 40)

The method of claim 40, wherein the pharmaceutical composition further comprises an excipient comprising binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, or a combination thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the pharmaceutical composition is an oil, an oil-in-water emulsion, a water-in-oil emulsion, or an aqueous solution.
